Biobanking Services Market Set for Steady Growth to US$ 81.68 Billion by 2033, Led by North America's 43.3% Market Share

The global Biobanking Services Market reached US$ 48.56 Billion in 2023, with a rise of US$ 51.00 Billion in 2024 and is expected to reach US$ 81.68 Billion by 2033, growing at a CAGR of 5.4% during the forecast period 2025-2033.

The market is steadily expanding as healthcare providers, research institutions, and biotech firms prioritize advanced sample storage, automated retrieval systems, and AI-integrated data management, driven by surging demand for precision medicine, genomics research, and personalized therapies. This growth underscores a shift toward scalable, compliant biobanks that enable faster drug discovery and clinical trials amid rising chronic disease burdens worldwide.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/biobanking-services-market?ram

Key Industry Developments

United States:
✅ March 2026: National Cancer Institute (Cancer Moonshot Biobank) expanded its longitudinal biospecimen collection network across U.S. community hospitals, increasing enrollment beyond 1,000 advanced‐cancer patients and systematizing multi‐site tissue and blood sample acquisition for translational research. Detailed clinical and outcomes‐linked data are being integrated into NCI‐managed repositories to support nationwide drug‐resistance and biomarker studies.

✅ February 2026: BioLife Solutions announced a capacity expansion of its U.S. biobanking and cryopreservation infrastructure to support scale‐up of cell and gene therapy manufacturing, adding extra controlled‐rate freezing and cryogenic storage capacity for commercial‐scale clinical‐trial programs. The upgrade is coupled with enhanced controlled‐environment logistics to maintain cell‐therapy viability across long‐term storage and distribution.

✅ January 2026: Thermo Fisher Scientific introduced an advanced biobanking‐dedicated module for its Nautilus LIMS platform, embedding specialized workflows for biospecimen inventory, chain‐of‐custody, and donor‐demographic tracking to streamline high‐volume biorepository operations. The module integrates with existing sample‐storage and analytics hardware stacks, enabling automated reporting and audit‐ready data governance for large‐scale U.S. biobanks.

Japan:
✅ October 2025: National Cancer Center Japan launched the "Liquid Biopsy Biobank," a dedicated repository collecting serial blood samples from cancer patients undergoing immunotherapy to support development of non‐invasive liquid‐biopsy diagnostics. The biobank is structured to standardize plasma and circulating tumor DNA collection protocols, enabling longitudinal monitoring of treatment response and resistance mechanisms.

✅ September 2025: Kyoto University Hospital deployed an automated robotic‐retrieval system within its biobank to extract samples at -80 °C without transient warming, preserving integrity for sensitive proteomic and metabolomic assays. The system reduces manual handling, minimizes frost‐related degradation, and improves traceability for high‐throughput clinical‐research cohorts.

✅ July 2025: RIKEN BioResource Research Center expanded its iPS‐cell‐based biobank with new HLA‐homozygous human‐induced pluripotent stem cell lines, broadening the availability of immunologically matched cell resources for regenerative‐medicine and drug‐safety studies. The expansion supports standardized in‐vitro disease modeling and toxicity screening for Japanese and global pharmaceutical partners.

Strategic Acquisitions and Partnerships
✅ Regeneron Pharmaceuticals completed the acquisition of 23andMe's biobank and genetics services business for approximately US$256 million in 2025, gaining access to a large genomic dataset to advance drug discovery and biobank-related research.

✅ Source BioScience acquired Cambridge Clinical Laboratories in April 2025, enhancing its diagnostics portfolio with personalized healthcare testing services and expanding clinical trial support capabilities relevant to biobanking.

✅ QIAGEN expanded its biobanking capabilities through the acquisition of a smaller firm specializing in sample preservation technologies in 2025, broadening its portfolio in automated workflows and sample integrity solutions.

Key Players:
Thermo Fisher Scientific Inc. | Tecan Trading AG | QIAGEN | Harrow Green Limited | TTP Labtech | UHN Biospecimen Services | VigiSolvo | Sampled | Crown Bioscience Company (Indivumed Services)

Strategic Leadership Analysis: Top 5 Key Players in the Biobanking Services Market 2026
-Thermo Fisher Scientific Inc.
Thermo Fisher has advanced its end‐to‐end biobanking solutions by integrating automated cryogenic storage, ambient‐to‐cryo sample handling workflows, and connected informatics platforms to support large‐scale precision‐medicine and cell‐therapy programs. The company recently enhanced its digital biobanking ecosystem with AI‐supported sample‐tracking and predictive‐analytics modules that improve sample‐traceability and reduce manual errors in high‐throughput repositories.

-QIAGEN
QIAGEN has strengthened its position as an integrated sample‐to‐insights partner by expanding its biobanking‐compatible extraction, stabilization, and pre‐analytical workflows, particularly for blood, saliva, and tissue‐based biobanks. In 2025, QIAGEN absorbed a specialized sample‐preservation and workflow‐automation firm, broadening its automated biobank‐ready workflows and sample‐integrity solutions to support longitudinal‐cohort and multi‐omics studies.

-Tecan Trading AG
Tecan has positioned itself as a leader in automated biobanking by deploying its liquid‐handling and sample‐management platforms for high‐throughput biobanks, enabling walk‐away automation of sample aliquoting, plate‐format conversion, and QC workflows. Recent iterations of its Fluent and Freedom EVO platforms include biobank‐specific scripting templates and barcode‐driven sample tracking that streamline integration with LIMS and centralize biobank data for clinical‐trial and cohort‐study applications.

-TTP Labtech
TTP Labtech has deepened its focus on sample‐integrity‐centric biobanking by advancing its automated cryogenic storage and ultra‐low‐temperature handling systems for high‐value biospecimens such as cell‐therapy and organoid samples. The provider has introduced compact, modular automated biobanking units that combine -80°C storage, gantry‐based robotics, and integrated sample‐tracking software, enabling smaller centers to deploy scalable, walk‐away biobanking without large‐footprint infrastructure.

-UHN Biospecimen Services (part of the University Health Network, Toronto)
UHN Biospecimen Services has reinforced its role as a clinical‐trial‐oriented biorepository network by expanding its centralized collection, processing, and storage infrastructure for oncology and precision‐medicine studies. The service has recently enhanced its virtual‐biobank interface and consent‐management tools, enabling researchers to remotely access annotated biospecimens and associated clinical data while maintaining strict governance, traceability, and FAIR‐data‐compliant metadata standards.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/biobanking-services-market?ram

Main Drivers and Trends Shaping the Future of Biobanking Services Market
-Personalized Medicine Surge: Rising demand for tailored therapies relies on high-quality biospecimens with annotated data, fueling biobank expansion in drug discovery and precision oncology.

-Chronic Disease Prevalence: Increasing cases of cancer, cardiovascular diseases, and other conditions drive the need for blood biomarkers and longitudinal sample storage for early detection research.

-Regenerative Medicine Growth: Stem cell storage and tissue engineering applications boost specialized biobanking, supporting innovative treatments in cardiology and oncology.

-Technological Advancements: Automation, AI-driven analytics, improved cryopreservation, and cloud-based solutions enhance sample integrity, efficiency, and data management scalability.

-Market Hurdles: High infrastructure costs, stringent regulatory compliance, and operational complexities in sample handling pose key constraints to widespread adoption.

Regional Insights:
-North America: 43.3% (Largest share, driven by advanced R&D infrastructure and precision medicine demand).

-Asia Pacific: 27% (Fastest growing, fueled by rising healthcare investments in China, India, and Japan).

-Europe: 36% (Strong position from regulatory frameworks and research networks).

Market Opportunities & Challenges: Biobanking Services Market 2026
-Opportunities: A "Precision Medicine Surge" accelerates demand for high-quality biospecimens; AI-powered multi-omics integration and blockchain traceability enable scalable regenerative medicine repositories. "One Health" frameworks with global collaborations, plus sustainable cryogenic innovations, de-risk investments in automated, eco-efficient biobanks.

-Challenges: Stringent GDPR-compliant data privacy mandates complicate cross-border sample sharing, while legacy ultra-low temperature infrastructure hikes energy costs amid net-zero pressures. Success demands mastering fragmented hybrid models blending centralized automation with decentralized IoT monitoring.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=biobanking-services-market?ram

Market Segmentation Analysis:
-By Service Type: DNA/RNA Biobanking Leads
DNA/RNA biobanking holds about 35% share, driven by genomics and precision‐medicine research requiring stable nucleic‐acid storage. Human tissue biobanking follows at 30%, underpinned by cancer and pathology biobanks. Stem cell biobanking captures 20%, fueled by regenerative and developmental research. Cord biobanking accounts for 10%, limited to perinatal and family‐planned banking. Other services (bioinformatics, sample‐quality testing, etc.) make up 5%.

-By Sample Type: Human Tissues Dominate
Human tissues represent roughly 35% share, supported by oncology and translational‐research demand. Blood products account for 30%, vital for immunology, infectious‐disease, and large‐cohort studies. Cell lines take 20%, essential for drug screening and reproducible assays. Nucleic acids hold 15%, tied to high‐throughput sequencing and biobanking.

-By Application: Life Science Leads
Life science research commands about 40% share, as biobanks underpin discovery and target‐validation programs. Clinical research follows at 35%, driven by trials‐linked biobanking and companion‐diagnostic development. Regenerative medicine accounts for 25%, growing with cell‐therapy and stem‐cell product pipelines.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.